Phase II study of prolonged oral @entity2879 in combination with intravenous XXXX in advanced @entity1149 .

@entity1 @entity137 @entity417 @entity882 @entity1149 @entity900 @entity2879 @entity177 @entity1503 @entity1398 @entity1431
The objectives of the study were to evaluate the combination of @entity900 and prolonged oral @entity2879 for response rate, survival, and @entity137 . The treatment regimen consisted of @entity2879 (50 mg/m2/day) p.o. for 21 consecutive days and @entity900 (100 mg/m2) i.v. on day 1 every 28 days for up to six courses. @entity1 with Stage IIIB or IV @entity1149 who had not received prior chemotherapy and had an ECOG performance status of 0-2 were eligible if they had normal bone marrow, @entity177 . @entity1 were followed weekly for @entity137 including complete blood counts. The total number of @entity1 entered in the study was 60, of whom 56 were male and four female, 40 white and 20 African Americans. Median age was 64 years (range, 39-77). Performance status 0, 1, and 2 was present in five, 39, and 16 @entity1 , respectively. Fourteen @entity1 had Stage IIIB and 46 Stage IV disease. A total of 142 treatment courses were administered (median 2, range 1-6). Three @entity1 had a complete response and 19 @entity1 had a partial response for an objective response rate of 37% (95% confidence interval, 31-43%). Median survival was 5 months (range, 1-39+). @entity1398 was the major @entity137 with Grade 4 occurring in 25 @entity1 after the first course. The following percent of @entity1 experienced severe or life-threatening @entity1503 (Grade 3 and 4 combined) over all courses: @entity1431 , 73%; @entity1398 , 73%; @entity417 , 42%; and @entity882 , 37%. Three @entity1 died of @entity1398 .(ABSTRACT TRUNCATED AT 250 WORDS)
